Risk factors

FDA staffing cuts and government shutdowns pose new clinical trial delay threats. AI adoption introduces cybersecurity and IP infringement risks. Legal battles with Eli Lilly continue with ongoing pre-trial motions.

The company added a specific disclosure regarding a March 1, 2025 cybersecurity incident causing a system outage.

The company relies heavily on patent monetization and ongoing litigations against firms like Citadel and Samsung. Remote Power patent revenue reached $188 million total through 2025 before enforcement stopped.

Onconetix pivoted its strategy by abandoning ENTADFI commercialization, settling its Veru debt, and pursuing the Realbotix transactions.

Geographic concentration in Los Angeles exposes profitability to local economic conditions and real estate markets.

Regulatory reviews now evaluate allowance for credit losses and financial assets measured at amortized cost.

Interest-rate disclosures now reflect 175 basis points of Federal Reserve cuts through December 2025 and a 3.75% upper limit in January 2026.

Added AI integration and macroeconomic risks while updating debt covenant violations and global conflicts.

Total assets increased by $46.0 million to $1.30 billion in 2025 as the balance sheet stabilized.

RideNow Group ceased its transportation brokerage business in December 2025, eliminating historical revenues and leaving residual transition costs.

Health care loan concentration increased from $167.3 million to $194.3 million.

Renatus Tactical Acquisition Corp I faces risks typical of a blank check company seeking an unspecified business combination.